US2009227768A1PendingUtilityA1
Anti-Allergic Complex Molecules
Est. expiryDec 21, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 37/08A61P 25/28A61P 27/14A61P 25/06A61P 17/04A61P 13/10C07K 14/70557A61K 47/64C07K 14/50A61P 17/06A61P 11/02C07K 19/00A61P 11/06A61P 1/00C07K 14/4722C07K 2319/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention discloses novel anti-allergic complex molecules, and in particular, peptidic or peptidomimetic molecules, that includes a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine secretion from mast cells and protein kinase activation, wherein the first part is connected to the second part via a linker or a direct bond that creates a conformational constraint by forming a bend or turn.
Claims
exact text as granted — not AI-modified1 . A complex molecule comprising a first segment at the N terminus competent for importation of said molecule into mast cells, and a second segment at the C terminal for preventing late phase inflammatory responses induced by mitogen activated protein kinase activation within said mast cells, said first segment being a peptide and joined to said second segment through a linker, said linker providing a bend or turn at the junction between the C terminal of said first segment and the N terminus of said second segment, with the proviso that the first segment is other than the peptide AAVALLPAVLLALLAP (SEQ ID NO:27), when the second segment is the anti-allergic decapeptide derived of the C-terminal end of Gαi3 (SEQ ID NO.: 1) or Got (SEQ ID NO.: 2), wherein said first segment comprises 10-50 amino acids having a hydrophobic, lipid soluble portion.
2 . The molecule of claim 1 , wherein the second segment of the molecule reduces the late phase inflammatory response by at least significantly reducing degranulation of said mast cells.
3 . The molecule of claim 1 , wherein the second segment of the molecule is selected from the group consisting of a peptide, a peptidomimetic, or a polypeptide.
4 . The molecule of claim 3 , wherein the second segment of the molecule is a peptide having a cyclic conformation stabilized by bonds selected from the group consisting of hydrogen bonds, ionic bonds and covalent bonds.
5 . The molecule of claim 1 , wherein the linker of the molecule is a covalent bond.
6 . The molecule of claim 5 , wherein the covalent bond is a peptide bond.
7 . The molecule of claim 1 , wherein the second segment of the molecule has an amino acid sequence selected from the group consisting of:
a decapeptide derived from Gαi 3 having the sequence KNNLKECGLY (SEQ ID NO: 1); a decapeptide derived from Gαt having the sequence KENLKDCGLF (SEQ ID NO:2);
KNNLKECGL-para-amino-F (SEQ ID NO:4); KQNLKECGLY (SEQ ID NO:5); KSNLKECGLY (SEQ ID NO:6); KNNLKEVGLY (SEQ ID NO:7); and KENLKECGLY (SEQ ID NO:8).
8 . The molecule of claim 1 , wherein the second segment of the molecule is a peptide taken from the C terminal sequence of Gαi 3 .
9 . The molecule of claim 1 , wherein the molecule is a peptide having an amino acid sequence selected from the group consisting of:
WALL006:
(SEQ ID NO:11)
AAVALLPAVLLALLAPKQNLKECGLY
WALL007:
(SEQ ID NO:12)
AAVALLPAVLLALLAPKNNLKEVGLY
WALL008:
(SEQ ID NO:13)
Succinyl-AAVALLPAVLLALLA-Sar-KNNLKECGLY
WALL010:
(SEQ ID NO:15)
VTVLALGALAGVGVGPKNNLKECGLY
WALL011:
(SEQ ID NO:16)
Succinyl - AAVALLPAVLLALLAPKSNLKECGLY
WALL012:
(SEQ ID NO:17)
Succinyl - AAVALLPAVLLALLAPKENLKLECGLY
WALL013:
(SEQ ID NO:18)
Succinyl - AAVALLPAVLLALLAPKANLKECGLY
WALL014:
(SEQ ID NO:19)
Succinyl - AAVALLPAVLLALLAP KNNLKECGL-para-amino-F
WALL015:
(SEQ ID NO:20)
Succinyl - AAVALLPAVLLALLAPKQNLKECGLY
WALL016:
(SEQ ID NO:21)
Succinyl - AAVALLPAVLLALLAPKNNLKEVGLY.
10 . The molecule of claim 1 , wherein the molecule is a peptide having an amino acid sequence selected from the group consisting of:Join the waitlist — get patent alerts
Track US2009227768A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.